William Blair & Company
VTGN icon

William Blair & Company’s VistaGen Therapeutics VTGN Stock Holding History

William Blair & Company’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,573
Closed -$44.6K – 1953
2025
Q3 		$44.6K Sell
12,573
-73,293
-85% -$219K ﹤0.01% 1653
2025
Q2 		$172K Sell
85,866
-15,000
-15% -$34.1K ﹤0.01% 1442
2025
Q1 		$252K Buy
100,866
+2,400
+2% +$6.79K ﹤0.01% 1312
2024
Q4 		$290K Buy
98,466
+10,000
+11% +$28.1K ﹤0.01% 1297
2024
Q3 		$266K Hold
88,466
– – ﹤0.01% 1331
2024
Q2 		$308K Buy
88,466
+20,000
+29% +$86.6K ﹤0.01% 1262
2024
Q1 		$362K Sell
68,466
-19,580
-22% -$94.1K ﹤0.01% 1185
2023
Q4 		$453K Buy
88,046
+2,873
+3% +$10.9K ﹤0.01% 1095
2023
Q3 		$446K Buy
+85,173
New +$378K ﹤0.01% 1095
2021
Q3 		– Sell
-407
Closed -$38K – 1947
2021
Q2 		$38K Buy
+407
New +$30.2K ﹤0.01% 1721
2020
Q1 		– Sell
-1,705
Closed -$35K – 1772
2019
Q4 		$35K Sell
1,705
-46,145
-96% -$1.17M ﹤0.01% 1525
2019
Q3 		$1.54M Buy
+47,850
New +$1.07M 0.01% 646

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

William Blair & Company's VTGN Position: Q4 2025 in Review

William Blair & Company sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 12,573 shares — an estimated $44.6K sold.

William Blair & Company first reported a position in VTGN in Q3 2019 and held it in 12 quarters. The position peaked at $1.54M in Q3 2019. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • William Blair & Company reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • William Blair & Company sold 12,573 VistaGen Therapeutics shares in Q4 2025, an estimated $44.6K.
  • William Blair & Company first reported a position in VistaGen Therapeutics in Q3 2019 and held it in 12 quarters.
  • William Blair & Company's VistaGen Therapeutics position peaked at $1.54M in Q3 2019.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on William Blair & Company's 13F filing for Q4 2025, filed 17 Feb 2026.